103 related articles for article (PubMed ID: 15995637)
1. Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma.
De Lucia D; De Francesco F; Marotta R; Maisto G; Meo D; Sessa M; Misso M; Galante M; Russo T; Pignalosa O; Napolitano M; Papa ML; Niglio A; Di Micco P
Exp Oncol; 2005 Jun; 27(2):159-61. PubMed ID: 15995637
[TBL] [Abstract][Full Text] [Related]
2. Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency.
Zöller B; Holm J; Svensson P; Dahlbäck B
Thromb Haemost; 1996 Feb; 75(2):270-4. PubMed ID: 8815575
[TBL] [Abstract][Full Text] [Related]
3. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
Dahlbäck B
Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
[TBL] [Abstract][Full Text] [Related]
4. The frequency of factor V Leiden and concomitance of factor V Leiden with prothrombin G20210A mutation and methylene tetrahydrofolate reductase C677T gene mutation in healthy population of Denizli, Aegean region of Turkey.
Kabukcu S; Keskin N; Keskin A; Atalay E
Clin Appl Thromb Hemost; 2007 Apr; 13(2):166-71. PubMed ID: 17456626
[TBL] [Abstract][Full Text] [Related]
5. Activated protein C resistance and the FV:R506Q mutation in a random population sample--associations with cardiovascular risk factors and coagulation variables.
Lowe GD; Rumley A; Woodward M; Reid E; Rumley J
Thromb Haemost; 1999 Jun; 81(6):918-24. PubMed ID: 10404768
[TBL] [Abstract][Full Text] [Related]
6. The factor V (FV) gene ASP79HIS polymorphism modulates FV plasma levels and affects the activated protein C resistance phenotype in presence of the FV Leiden mutation.
Bossone A; Cappucci F; D'Andrea G; Brancaccio V; Cibelli G; Iannaccone L; Grandone E; Margaglione M
Haematologica; 2003 Mar; 88(3):286-9. PubMed ID: 12651267
[TBL] [Abstract][Full Text] [Related]
7. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
[TBL] [Abstract][Full Text] [Related]
8. Congenital and acquired activated protein C resistance.
Nicolaes GA; Dahlbäck B
Semin Vasc Med; 2003 Feb; 3(1):33-46. PubMed ID: 15199491
[TBL] [Abstract][Full Text] [Related]
9. Association of elevated levels of prothrombin fragment 1+2 and Arg506 to Gln mutation in patients with a history of ischemic stroke.
De Lucia D; Papa ML; Ammendola F; Pezzella S; Del Giudice V; Marotta R; Renis V; Di Mauro C; Maisto G; Masi S; Nina P; Franco A; Schisano G
J Neurosurg Sci; 1999 Mar; 43(1):45-50; discussion 50-1. PubMed ID: 10494665
[TBL] [Abstract][Full Text] [Related]
10. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
Favaloro EJ; Mirochnik O; McDonald D
Br J Biomed Sci; 1999; 56(1):23-33. PubMed ID: 10492912
[TBL] [Abstract][Full Text] [Related]
11. Activated protein C resistance in anterior ischaemic optic neuropathy.
Nagy V; Facsko A; Takacs L; Balazs E; Berta A; Balogh I; Edes I; Czuriga I; Pfliegler G
Acta Ophthalmol Scand; 2004 Apr; 82(2):140-3. PubMed ID: 15043529
[TBL] [Abstract][Full Text] [Related]
12. [Activated C protein resistance: laboratory study and prevalence of the defect in the Chilean population].
Pereira J; Quiroga T; Goycoolea M; Muñoz B; Hidalgo P; Kaltwasser G; Mezzano D
Rev Med Chil; 1996 Jun; 124(6):663-8. PubMed ID: 9041721
[TBL] [Abstract][Full Text] [Related]
13. Factor V Leiden mutation in one family of Chinese origin.
Wu J; Gu J; Xu J; Wang J; Sun Z; Smirnov MD; Morrissey JH; Esmon N
Chin Med J (Engl); 2001 Apr; 114(4):379-81. PubMed ID: 11780458
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
Guasch JF; Lensen RP; Bertina RM
Thromb Haemost; 1997 Feb; 77(2):252-7. PubMed ID: 9157576
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of phenotype resistance to activated protein C (APC resistance)].
Hudecek J; Ivanková J; Dobrotová M; Hybenová J; Pullmann R; Kubisz P
Vnitr Lek; 1999 Dec; 45(12):723-8. PubMed ID: 10951849
[TBL] [Abstract][Full Text] [Related]
16. Intraindividual consistency of the activated protein C resistance phenotype.
Tosetto A; Simioni M; Madeo D; Rodeghiero F
Br J Haematol; 2004 Aug; 126(3):405-9. PubMed ID: 15257714
[TBL] [Abstract][Full Text] [Related]
17. The VITA Project: heritability of resistance to activated protein C. Vincenza Thrombophilia and Arteriosclerosis.
Tosetto A; Castaman G; Cappellari A; Rodeghiero F
Thromb Haemost; 2000 Nov; 84(5):811-4. PubMed ID: 11127861
[TBL] [Abstract][Full Text] [Related]
18. The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza Thrombophilia and Atherosclerosis.
Tosetto A; Missiaglia E; Gatto E; Rodeghiero F
Thromb Haemost; 1997 Aug; 78(2):859-63. PubMed ID: 9268185
[TBL] [Abstract][Full Text] [Related]
19. Activated protein C resistance--a major risk factor for thrombosis.
Rosén SB; Sturk A
Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
[TBL] [Abstract][Full Text] [Related]
20. [Diagnosis of thrombophilia based on coagulation and genetic studies].
Bałszan-Kowalska I
Ann Acad Med Stetin; 2002; 48():179-93. PubMed ID: 14601477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
